# A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML

> **NCT05641259** · PHASE1 · UNKNOWN · sponsor: **Guangzhou Lupeng Pharmaceutical Company LTD.** · enrollment: 198 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
- Chronic Myelomonocytic Leukemia

## Interventions

- **DRUG:** LP-108
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT05641259
- **Lead sponsor:** Guangzhou Lupeng Pharmaceutical Company LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-02-14
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 198 (ESTIMATED)
- **Last updated:** 2024-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05641259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05641259, "A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05641259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*